Ann: Imugene Phase 1 onCARlytics CD19 virus clinical trial opens, page-134

Hi egobar,
Examples of acceptable late-breaking abstracts include the following (in each case, results were not available or significant by the regular abstract submission deadline):
 Results of a practice-changing prospective Phase III clinical trial
 Phase II study showing anti-tumor activity in a novel context
 An early clinical trial with novel proof-of-principle data
 Demonstration of novel cancer biology with therapeutic implications
For late-breaking abstracts, authors need to justify why the abstract is considered late-breaking, for
both clinical and laboratory-based studies.
The data in the abstract must not be published prior to the SITC 38th Annual Meeting.
Late-breaking abstracts are considered for—but not limited to—oral abstract presentations during the Late-Breaking Abstract Sessions from 11:45 a.m.–12:15 p.m. on Nov. 3, 2023, and 11:25–11:55 a.m. on Nov. 4, 2023.

Regards.